FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:35-45 January 1, 1998 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Quinidine is the most frequently prescribed antiarrhythmic drug,¹ despite unease about its possible proarrhythmic actions. That caution is required with the use of quinidine was, however, recognized early. Although the beneficial effect of quinine on "rebellious palpitations" was described in the 18th century,² it was noted almost from the outset that small doses of the more effective d-stereoisomer, quinidine, could occasionally result in dangerous idiosyncratic reactions.³

Initially used for cardioversion in patients with atrial fibrillation, quinidine was subsequently used widely as an antiarrhythmic drug, since it is less immunotoxic than procainamide and is without the anticholinergic, negatively inotropic actions . . . [Full Text of this Article]

Pharmacokinetics

Electrophysiologic Effects

Cellular Effects

Integrated Effects

Antiarrhythmic Actions

Clinical Efficacy

Atrial Fibrillation

Ventricular Arrhythmias

Adverse Effects

Proarrhythmia

Mortality

Other Adverse Effects

Drug Interactions

Conclusions

Source Information

From the Departments of Medicine and Biochemistry, University of Cambridge, and the Department of Cardiology, Papworth Hospital, Cambridge, United Kingdom (A.A.G.); and the Department of Cardiological Sciences, St. George's Hospital Medical School, London (A.J.C.).

Address reprint requests to Dr. Camm at the Department of Cardiological Sciences, Cranmer Terr., London SW17 0RE, United Kingdom.

References

This article has been cited by other articles:

• Pires, M. M., Emmert, D., Hrycyna, C. A., Chmielewski, J. (2009). Inhibition of P-Glycoprotein-Mediated Paclitaxel Resistance by Reversibly Linked Quinine Homodimers. Mol. Pharmacol. 75: 92-100 [Abstract] [Full Text]  
• Spitzner, M., Ousingsawat, J., Scheidt, K., Kunzelmann, K., Schreiber, R. (2007). Voltage-gated K+ channels support proliferation of colonic carcinoma cells. FASEB J. 21: 35-44 [Abstract] [Full Text]  
• Pope, L. E., Khalil, M. H., Berg, J. E., Stiles, M., Yakatan, G. J., Sellers, E. M. (2004). Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor Metabolizers. J Clin Pharmacol 44: 1132-1142 [Abstract] [Full Text]  
• Sanchez-Chapula, J. A., Ferrer, T., Navarro-Polanco, R. A., Sanguinetti, M. C. (2003). Voltage-Dependent Profile of Human Ether-a-go-go-Related Gene Channel Block Is Influenced by a Single Residue in the S6 Transmembrane Domain. Mol. Pharmacol. 63: 1051-1058 [Abstract] [Full Text]  
• Franks, C. J., Pemberton, D., Vinogradova, I., Cook, A., Walker, R. J., Holden-Dye, L. (2002). Ionic Basis of the Resting Membrane Potential and Action Potential in the Pharyngeal Muscle of Caenorhabditis elegans. J. Neurophysiol. 87: 954-961 [Abstract] [Full Text]  
• Ngui, J. S., Chen, Q., Shou, M., Wang, R. W., Stearns, R. A., Baillie, T. A., Tang, W. (2001). In Vitro Stimulation of Warfarin Metabolism by Quinidine: Increases in the Formation of 4'- and 10-Hydroxywarfarin. Drug Metab. Dispos. 29: 877-886 [Abstract] [Full Text]  
• RuDusky, B. M., Alpert, M. A. (2001). Quinidine as an Antiarrhythmic. Chest 119: 1617-1619 [Full Text]  
• Albrecht, H., Lennox, J., del Rio, C., Dorsey, G., Rosenthal, P. J. (2001). Quinidine and Malaria. Arch Intern Med 161: 1118-1119 [Full Text]  
• Grossmann, M., Dobrev, D., Himmel, H. M., Ravens, U., Kirch, W. (2001). Ascorbic Acid-Induced Modulation of Venous Tone in Humans. Hypertension 37: 949-954 [Abstract] [Full Text]  
• Tang, W., Stearns, R. A., Kwei, G. Y., Iliff, S. A., Miller, R. R., Egan, M. A., Yu, N. X., Dean, D. C., Kumar, S., Shou, M., Lin, J. H., Baillie, T. A. (1999). Interaction of Diclofenac and Quinidine in Monkeys: Stimulation of Diclofenac Metabolism. J. Pharmacol. Exp. Ther. 291: 1068-1074 [Abstract] [Full Text]  
• Catherwood, E., Fitzpatrick, W. D., Greenberg, M. L., Holzberger, P. T., Malenka, D. J., Gerling, B. R., Birkmeyer, J. D. (1999). Cost-Effectiveness of Cardioversion and Antiarrhythmic Therapy in Nonvalvular Atrial Fibrillation. ANN INTERN MED 130: 625-636 [Abstract] [Full Text]  
• Nenov, N. I., Crumb, W. J. Jr, Pigott, J. D., Harrison, L. H. Jr, Clarkson, C. W. (1998). Quinidine Interactions With Human Atrial Potassium Channels : Developmental Aspects. Circ. Res. 83: 1224-1231 [Abstract] [Full Text]  
• Eckman, M. H., Falk, R. H., Pauker, S. G. (1998). Cost-effectiveness of Therapies for Patients With Nonvalvular Atrial Fibrillation. Arch Intern Med 158: 1669-1677 [Abstract] [Full Text]